ABOUT US  |  CONTACT US  |  RSS  |  ARCHIVE  |  2023-03-25  |  UPDATED: 1400/12/03 - 17:55:1 FA | AR | PS | EN
Russia says open to diplomacy over Ukraine, defends recognition of breakaway regions             Pakistan steps up military operation along Durand Line             Ghani Removed From UN Heads of State List             President Lukashenko: Belarus may purchase Russian S-400 missile systems             Iran rejects Reuters report on deal in Vienna talks as effort to boost Western sides standing             Police throng Ottawa streets in preparation for crackdown on protests            Taliban Delegation Returns to Kabul from Doha             US General: Daesh Concerns Us in Afghanistan             Afghan Women Criticize Bidens Afghan Assets Decision             Afghan U19 Futsal Team Beats Uzbekistan 8-1             Nazi salute shakes up EU parliament             NY attorney general fires back at Trumps defense of financial statements             Ethnic Russians in eastern Ukraine say attacked by govt. forces             NJ police cuff Black teen in fight as white teen watches showdown             US sends F-35 jets to Germany amid rising tensions in Eastern Europe            


DATE PUBLISHED: 1400/10/11 - 23:11:3
VISIT: 1090
SHARE WITH YOUR FRIENDS

Mixing Pfizer, AstraZ COVID-19 shots with Moderna gives better immune response: UK study


A teenager receives a dose of a vaccine against COVID-19 in a tent at Copacabana beach in Rio de Janeiro, Brazil, on December 31, 2021. (Photo by AFP)

A major British study into mixing COVID-19 vaccines has found that people had a better immune response when they received a first dose of AstraZeneca or Pfizer-BioNTech shots followed by Moderna nine weeks later, according to the results on Monday.

"We found a really good immune response across the board..., in fact, higher than the threshold set by Oxford-AstraZeneca vaccine two doses," Matthew Snape, the Oxford professor behind the trial dubbed Com-COV2, told Reuters.

The findings supporting flexible dosing will offer some hope to poor and middle income countries which may need to combine different brands between first and second shots if supplies run low or become unstable.

"I think the data from this study will be especially interesting and valuable to low- and middle-income countries where theyre still rolling out the first two doses of vaccines," Snape said.

"Were showing...you dont have to stick rigidly to receiving the same vaccine for a second dose...and that if the program will be delivered more quickly by using multiple vaccines, then it is okay to do so."

If the AstraZeneca-Oxford vaccine is followed by a Moderna or Novavax shot, higher antibodies and T-cell responses were induced versus two doses of AstraZeneca-Oxford, according to researchers at the University of Oxford.

The study of 1,070 volunteers also found that a dose of the Pfizer-BioNTech (PFE.N), (22UAy.DE) vaccine followed by a Moderna shot was better than two doses of the standard Pfizer-BioNTech course.

Pfizer-BioNTech followed by Novavax induced higher antibodies than the two-dose Oxford-AstraZeneca schedule, although this schedule induced lower antibody and T-cell responses than the two-dose Pfizer-BioNTech schedule.

No safety concerns were raised, according to the Oxford University study published in the Lancet medical journal.

Many countries have been deploying a mix and match well before robust data was available as nations were faced with soaring infection numbers, low supplies and slow immunization over some safety concerns.

Longevity of protection offered by vaccines has been under scrutiny, with booster doses being considered as well amid surging cases. New variants, including Delta and Omicron, have now increased the pressure to speed up vaccination campaigns.

Blood samples from participants were tested against the Wild-Type, Beta and Delta variants, researchers of the Com-COV2 study said, adding that vaccines efficacy against the variants had waned, but this was consistent across mixed courses.

Deploying vaccines using technology from different platforms - like Pfizer and Modernas mRNA, AstraZenecas viral vector and Novavaxs protein-based shot - and within the same schedule is new.

The results may inform new approaches to immunization against other diseases, he said.

The study also found that a first dose of the AstraZeneca-Oxford vaccine followed by any of the other candidates in the study generated a particularly robust response, consistent with findings in June.

The study was designed as a so-called "non-inferiority" study - the intent is to demonstrate that mixing is not substantially worse than the standard schedules - and compares the immune system responses to the gold-standard responses reported in previous clinical trials of each vaccine.

 

(Source: Reuters)

 

LINK: https://www.ansarpress.com/english/25526


TAGS:






*
*

*



SEE ALSO

Ukraine considering cutting ties with Russia


Russia says open to diplomacy over Ukraine, defends recognition of breakaway regions


President Lukashenko: Belarus may purchase Russian S-400 missile systems


Police throng Ottawa streets in preparation for crackdown on protests


Nazi salute shakes up EU parliament


Ethnic Russians in eastern Ukraine say attacked by govt. forces


US sends F-35 jets to Germany amid rising tensions in Eastern Europe


Western leaders should see doctor over Ukraine paranoia, says Russian envoy


Putin: Russia does not want war, ready to continue security talks with West


Indias hijab row spreads to its most populous state





VIEWED
MOST DISCUSSED




POLL

Modi, Merkel Discuss Afghanistan, Radicalisation And Terrorism

SEE RESULT


LAST NEWS

Ukraine considering cutting ties with Russia

Russia says open to diplomacy over Ukraine, defends recognition of breakaway regions

Pakistan steps up military operation along Durand Line

Ghani Removed From UN Heads of State List

President Lukashenko: Belarus may purchase Russian S-400 missile systems

Iran rejects Reuters report on deal in Vienna talks as effort to boost Western sides standing

Police throng Ottawa streets in preparation for crackdown on protests

Taliban Delegation Returns to Kabul from Doha

US General: Daesh Concerns Us in Afghanistan

Afghan Women Criticize Bidens Afghan Assets Decision

Afghan U19 Futsal Team Beats Uzbekistan 8-1

Nazi salute shakes up EU parliament

NY attorney general fires back at Trumps defense of financial statements

Ethnic Russians in eastern Ukraine say attacked by govt. forces

NJ police cuff Black teen in fight as white teen watches showdown

US sends F-35 jets to Germany amid rising tensions in Eastern Europe

Talks on Outsourced Airport Operations Still Ongoing: Ministry

EU to deliver Є500 million to Afghan people

Atmars Letter to UN Regarding Afghan Mission Denied: Faiq

Afghan Embassy in US Facing Financial Problems

Karzai: Afghan Girls Must Definitely Return to School

US support for the Taliban/ US supports no armed movement against Afghan government: Envoy

South Korea may punish Tesla

Central bank calls on India to ban cryptocurrency

Three women will host this years Oscars, while ratings continue to plummet

Western leaders should see doctor over Ukraine paranoia, says Russian envoy

GOP boycotts Biden Fed nominees vote as bank fights inflation

Europe pledges $11 M to Afghanistans educational sector

Four dead, 17 missing as Spain trawler sinks off Canada

Putin: Russia does not want war, ready to continue security talks with West

Indias hijab row spreads to its most populous state

Israel trying to sabotage Vienna process as talks enter sensitive stage: Report

Kremlin: US talk of imminent Ukraine invasion baseless hysteria

Moderate Democrats fear party infighting could cost them Congress

NBA: Chicago Bulls 120-109 San Antonio Spurs

Afghan Delegates Meet EU Envoys in Doha

UK to Co-Host Afghan Aid Virtual Summit

Afghanistan U19 Futsal Team Beats Tajikistan

Pakistan denies ISI chief meeting Afghan Jihadi leaders in Turkey

IRC urges US, Europe to reset their policies towards Afghanistan before humanitarian crisis kills more Afghans


MEDICAL NEWS


ANSAR PRESS  |  ABOUT US  |  CONTACT US  |  MOBILE VERSION  |  LINKS  |  DESIGN: Negah Network Co.
All right reserved. Use this website by mentioning the source (link) is allowed. Ԑ یی